Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Apr 30:5:118.
doi: 10.3389/fmed.2018.00118. eCollection 2018.

Considering Cell Therapy Product "Good Manufacturing Practice" Status

Patrick Bedford  1 , Juliana Jy  1 , Lucas Collins  1 , Steven Keizer  1
Affiliations

Considering Cell Therapy Product "Good Manufacturing Practice" Status

Patrick Bedford et al. Front Med (Lausanne). .
No abstract available

Keywords: cell therapy; clinical trials; good manufacturing practices; international perspective; manufacturing; regulatory.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Isasi R, Rahimzadeh V, Charlebois K. Uncertainty and innovation: understanding the role of cell-based manufacturing facilities in shaping regulatory and commercialization environments. Appl Transl Genom (2016) 11:27–39.10.1016/j.atg.2016.11.001 - DOI - PMC - PubMed
    1. George B. Regulations and guidelines governing stem cell based products: clinical considerations. Perspect Clin Res (2011) 2(3):94–9.10.4103/2229-3485.83228 - DOI - PMC - PubMed
    1. Yano K, Watanabe N, Tsuyuki K, Ikawa T, Kasanuki H, Yamato M. Regulatory approval for autologous human cells and tissue products in the United States, the European Union, and Japan. Regener Ther (2015) 1:45–56.10.1016/j.reth.2014.10.001 - DOI - PMC - PubMed
    1. Hartmann K, Schubler-Lenz M, Bondanza A, Buchholz CJ. Clinical development of CAR T cells – challenges and opportunities in translating innovative treatment concepts. EMBO Mol Med (2017) 9(9):1183–97.10.15252/emmm.201607485 - DOI - PMC - PubMed
    1. Krackhardt AM, Anliker B, Hildebrandt M, Bachmann M, Eichmuller SB, Nettlebeck DM, et al. Clinical translation and regulatory aspects of CAR/TCR-based adoptive cell therapies – the German Cancer Consortium approach. Cancer Immunol Immunother (2018) 67(4):513–23.10.1007/s00262-018-2119-y - DOI - PMC - PubMed

LinkOut - more resources